Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma
- PMID: 24495592
- DOI: 10.1016/j.ijrobp.2013.12.011
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma
Abstract
Purpose/objectives: To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM).
Methods and materials: All patients underwent postsurgical hypofractionated high-dose IMRT. Three layered planning target volumes (PTVs) were contoured. PTV1 was the surgical cavity and residual tumor on T1-weighted magnetic resonance images with 5-mm margins, PTV2 was the area with 15-mm margins surrounding the PTV1, and PTV3 was the high-intensity area on fluid-attenuated inversion recovery images. Irradiation was performed in 8 fractions at total doses of 68, 40, and 32 Gy for PTV1, PTV2, and PTV3, respectively. Concurrent TMZ was given at 75 mg/m(2)/day for 42 consecutive days. Adjuvant TMZ was given at 150 to 200 mg/m(2)/day for 5 days every 28 days. Overall and progression-free survivals were evaluated.
Results: No acute IMRT-related toxicity was observed. The dominant posttreatment failure pattern was dissemination. During a median follow-up time of 16.3 months (range, 4.3-80.8 months) for all patients and 23.7 months (range, 12.4-80.8 months) for living patients, the median overall survival was 20.0 months after treatment. Radiation necrosis was diagnosed in 20 patients and was observed not only in the high-dose field but also in the subventricular zone (SVZ). Necrosis in the SVZ was significantly correlated with prolonged survival (hazard ratio, 4.08; P=.007) but caused deterioration in the performance status of long-term survivors.
Conclusions: Hypofractionated high-dose IMRT with concurrent and adjuvant TMZ altered the dominant failure pattern from localized to disseminated and prolonged the survival of patients with GBM. Necrosis in the SVZ was associated with better patient survival, but the benefit of radiation to this area remains controversial.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1066-74. doi: 10.1016/j.ijrobp.2010.07.021. Epub 2010 Oct 6. Int J Radiat Oncol Biol Phys. 2011. PMID: 20932651 Clinical Trial.
-
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5. Int J Radiat Oncol Biol Phys. 2012. PMID: 22483738 Clinical Trial.
-
A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):92-7. doi: 10.1016/j.ijrobp.2009.04.064. Epub 2009 Aug 14. Int J Radiat Oncol Biol Phys. 2010. PMID: 19683876 Clinical Trial.
-
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.J Neurooncol. 2012 Apr;107(2):395-405. doi: 10.1007/s11060-011-0766-3. Epub 2011 Nov 22. J Neurooncol. 2012. PMID: 22105851 Review.
-
The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.J Neurooncol. 2020 Nov;150(2):215-267. doi: 10.1007/s11060-020-03612-7. Epub 2020 Nov 19. J Neurooncol. 2020. PMID: 33215344
Cited by
-
Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide.J Neurooncol. 2016 Oct;130(1):165-170. doi: 10.1007/s11060-016-2228-4. Epub 2016 Aug 17. J Neurooncol. 2016. PMID: 27535747
-
Effect of radiation dose to the periventricular zone and subventricular zone on survival in anaplastic gliomas.Ecancermedicalscience. 2019 Jul 31;13:956. doi: 10.3332/ecancer.2019.956. eCollection 2019. Ecancermedicalscience. 2019. PMID: 31645884 Free PMC article.
-
Construction of a novel radiosensitivity- and ferroptosis-associated gene signature for prognosis prediction in gliomas.J Cancer. 2022 May 20;13(8):2683-2693. doi: 10.7150/jca.72893. eCollection 2022. J Cancer. 2022. PMID: 35711838 Free PMC article.
-
Advances in Radiotherapy for Glioblastoma.Front Neurol. 2018 Jan 15;8:748. doi: 10.3389/fneur.2017.00748. eCollection 2017. Front Neurol. 2018. PMID: 29379468 Free PMC article. Review.
-
Should the subventricular zone be part of the "rad" zone?J Neurooncol. 2014 Jun;118(2):423-424. doi: 10.1007/s11060-014-1465-7. Epub 2014 May 23. J Neurooncol. 2014. PMID: 24852419 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical